Nabriva Therapeutics Plc Receivables

Nabriva Therapeutics Plc (NBRV) currently reports a receivables of $11M as of March 2023. That compares with $11M in the prior-year period — down 4.5% year over year. Use the charts on this page to explore Nabriva Therapeutics Plc's receivables history and peer comparisons.

Nabriva Therapeutics Plc's receivables decreased from $11M to $11M — a 4.5% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Nabriva Therapeutics Plc reported $11M in receivables as of March 2023. That compares with $11M in the prior-year period — down 4.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Nabriva Therapeutics Plc, and consider following NBRV for alerts when major investors trade the stock.

Nabriva Therapeutics Plc is classified in the Healthcare sector. On receivables, it currently shows $11M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NBRV with unrelated industries.